CompletedPhase 1NCT03929016

Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Drugs for Neglected Diseases
Principal Investigator
Sharan Sidhu, MD
Quotient Sciences
Intervention
DNDI-0690(drug)
Enrollment
64 target
Eligibility
18-60 years · All sexes
Timeline
2019 – 2020

Study locations (1)

Collaborators

Wellcome Trust

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03929016 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials